Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr;15(4):422-30.
doi: 10.1177/1352458508101944.

Anti-alpha-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event

M S Freedman  1 , J Laks, N Dotan, R T Altstock, A Dukler, C J M Sindic
Affiliations

Anti-alpha-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event

M S Freedman et al. Mult Scler. 2009 Apr.

Abstract

Background: There is no specific serum-based biomarker for the diagnosis or prognosis of relapsing-remitting multiple sclerosis (RRMS).

Objective: We investigated whether levels of IgM antibodies to Glc(alpha1,4)Glc(alpha) (GAGA4) or to a panel of four glucose-based glycans could differentiate MS from other neurological diseases (OND) or predict risk of early relapse following first presentation (FP) of RRMS.

Methods: Retrospective analysis of 440 sera samples of three cohorts: A) FP-RRMS (n = 44), OND (n = 44); B) FP-RRMS (n = 167), OND (n = 85); and C) FP (n = 100). Anti-GAGA4 IgM levels were measured by enzyme immunoassay in cohort-A and cohort-B. Cohort-C IgM antibodies to glucose-based glycan panel were measured by immunofluorescence.

Results: FP-RRMS had higher levels of anti-GAGA4 IgM than OND patients (cohort-A, P = 0.01; cohort-B, P = 0.0001). Sensitivity and specificity were 27% and 97% for cohort-A; and 26% and 90% for cohort-B, respectively. In cohort-C, 58 patients experienced early relapse (<24 months), 31 had late relapse (> or =24 months), and 11 did not experience second attack during follow-up. Kaplan-Meier curves demonstrated decrease in time to next relapse for patients positive for the antibody panel (P = 0.02, log rank).

Conclusions: Serum anti-GAGA4 IgM discerns FP-RRMS patients from OND patients. Higher levels of serum anti-alpha-glucose IgM in FP patients predict imminent early relapse.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Glycan array format: A – Glass slide patterned with Teflon mask creating 7 clusters of microwells, 32 wells in each cluster. B – An adhesive silicon superstructure attached to the slide defines wells for manual application of multiple serum samples per slide. C – Antigens and controls lay out in each gasket well.
Figure 2
Figure 2
Distribution of anti-GAGA4 IgM levels in cohort-A [FP (n = 44) and OND (n = 44) patients]. Lines indicate SD ± mean. Crossing line indicates cutoff for defining antibody status. P-value (Mann–Whitney U) is FP group versus OND.
Figure 3
Figure 3
Distribution of anti-GAGA4 IgM levels in cohort-B [FP patients (n = 167), and OND (n = 85)]. Lines indicate SD ± mean. Crossing line indicates cutoff value for antibody status. P-value (Mann-Whitney U) is FP group versus OND.
Figure 4
Figure 4
Time to CDMS, Kaplan–Meier, survival plot for cohort-C. FP patients positive for ≥1 (anti-GAGA4, -GAGA2, -GAGA3, or -GAGA6 IgM) versus patients negative for all markers. Cutoff values were 4.0, 4.5, 4.5, and 4.3 for anti-GAGA2, -GAGA3, -GAGA4, and -GAGA6 IgM, respectively. P-values determined by log rank test. With Bonferroni correction only P-values below 0.0125 are considered significant.
See this image and copyright information in PMC

References

    1. Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005;62:865–870 - PubMed
    1. Lolli F, Mulinacci B, Carotenuto A, et al. An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis. Proc Natl Acad Sci USA 2005;102:10273–10278 - PMC - PubMed
    1. Lolli F, Mazzanti B, Pazzagli M, et al. The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. J Neuroimmunol 2005;167:131–137 - PubMed
    1. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003;349:139–145 - PubMed
    1. Kuhle J, Pohl C, Mehling M, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007;356:371–378 - PubMed

MeSH terms

LinkOut - more resources